** Brokerage Stifel raises PT on drugmaker Alnylam Pharmaceuticals' ALNY.O to $345 from $300 following expanded U.S. approval for its heart disease drug
** The new PT represents a 28.5% upside to the stock's last close
** Brokerage believes ALNY's drug Amvuttra will be a "go-to therapy" for patients with heart disease condition who progress on a stabilizer
** Amvuttra, a quarterly injection, was cleared to treat ATTR-CM, a condition where faulty transthyretin proteins accumulate in the heart and potentially causing organ to fail
** Stifel says physician feedback on the drug has been broadly favorable
** Twenty four of 31 brokerages rate the stock "buy" or higher, 7 "hold"; their median PT is $316.71, according to data compiled by LSEG
** As of last close, ALNY has risen 80% in past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。